Evidence map›Paper›PMID 40410329›Full record

ArticleEuropean radiology2025

Safety of radiofrequency ablation in patients with hyperparathyroidism: a 10-year real-world multicenter experience.

Tingting Jiang, Huihui Chai, Xuexia Shan, Erya Deng, Songyuan Yu, Xiaowan Bo, Xiaolong Li, Hongfeng He, Zhengxian Zhang, Ning Weng and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tingting Jiang *Center of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Huihui Chai *Center of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Xuexia Shan *Center of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Erya DengCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Songyuan YuCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiaowan BoCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiaolong LiDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Hongfeng HeDepartment of Ultrasound, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Zhengxian ZhangDepartment of Ultrasound, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China.
Ning WengDepartment of Nephrology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China.
Xiachuan QinDepartment of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jing FanDepartment of Ultrasound, Yiwu Fuyuan Hospital, Yiwu, China.
Xiaoqing TangDepartment of Ultrasound, Yiwu Fuyuan Hospital, Yiwu, China.
Wei HengDepartment of Ultrasound, The First People's Hospital of Aksu, Xinjiang, China.
Yong LiDepartment of Nephrology, The First People's Hospital of Aksu, Xinjiang, China.
Jiaxin LiCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Jinge ZhuCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Huili ZhangCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Liping SunCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. sunliping_s@126.com.
Chengzhong PengCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. pcz001@126.com.ORCID http://orcid.org/0000-0003-4886-7466
Wenwen YueCenter of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. yuewen0902@163.com.
Huixiong XuDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

National Natural Science Foundation of China 82272005
6 · The paper itself

Abstract

backgroundUS-guided percutaneous radiofrequency ablation (RFA) is a validated procedure for hyperparathyroidism (HPT). However, it is associated with potentially significant complications, and data regarding the incidence and risk factors associated with RFA-related complications are limited.

objectiveTo assess the complication rates associated with RFA for HPT and identify the potential influential factors.

methodsThis retrospective study was to investigate the associated complications in HPT patients who underwent RFA between January 2013 and April 2024. We collected and analyzed complications for these patients, focusing on their categories and rates. Logistic regression analysis was used to assess the crucial factors.

resultsThree hundred twenty patients were included, including 117 cases of primary hyperparathyroidism (pHPT) and 203 cases of secondary hyperparathyroidism (sHPT). The overall complication rate was 22.2% (71/320), with 9.4% (30/320) being major complications and 14.7% (47/320) minor complications. Six patients experienced both major and minor complications. Among sHPT patients, 54 cases (26.6%, 54/203) experienced complications, including 22 major cases and 36 minor cases; however, among pHPT patients, 17 cases experienced complications (14.5%, 17/117), with 8 being major and 11 being minor. sHPT was identified as a risk factor for overall complications (odds ratio, 2.132; p = 0.014) and minor complications (odds ratio, 2.077; p = 0.046). Maximum diameter was the only risk factor for major complications (odds ratio, 1.508, p = 0.047).

conclusionsRFA is a well-tolerated technique with an acceptably low incidence of major complications for HPT. Enhanced management strategies involving patients with sHPT and large hyperplastic glands may help mitigate complications. KEY POINTS: Question Is ultrasound-guided RFA a safe nonsurgical alternative to traditional parathyroidectomy for patients with pHPT and sHPT who require intervention? Findings Ultrasound-guided RFA is a safe procedure for treating HPT. However, patients with sHPT and large hyperplastic glands are more likely to develop complications. Clinical relevance RFA is a well-accepted technique with a relatively low complication rate and can be used as a non-surgical alternative in the management of HPT.

Indexed as

HyperparathyroidismPostoperative ComplicationsRadiofrequency AblationAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsUltrasonography, InterventionalHyperparathyroidismPrimary hyperparathyroidismRadiofrequency ablationSecondary hyperparathyroidismUltrasound

Identifiers

PMID40410329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.